Information Provided By: 
Fly News Breaks for July 29, 2019
NVCR
Jul 29, 2019 | 06:50 EDT
As previously reported, SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48. The analyst says that he has long recognized the stock as an "under-the-radar" oncology investment story that calls for investor attention, but notes that the interest and excitement about Optune's potential in future indications is growing. Gilbert notes that his updated model now includes "probability adjusted" sales for Phase 3 indications with some areas of "potential conservatism".
News For NVCR From the Last 2 Days
There are no results for your query NVCR
